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Impaired HCV Clearance in HIV/HCV Coinfected
Subjects Treated with PegIFN and RBV Due to Interference
of IFN Signaling by IFNaR2a
Yu-Jin Lee,1 Xiaozhen Zhang,1 Estefania Vazquez,2 Gayathri Shivasabesan,1 Howard A. Young,3
Alison Murphy,1 Honghui Wang,4 Anthony F. Suffredini,4 Ulrich Siebenlist,2 and Shyam Kottilil1
Enhanced endogenous interferon (IFN) stimulated gene (ISG) signature has been associated with nonrespon-
siveness to hepatitis C treatment using pegylated-IFNa (pegIFNa) and ribavirin (RBV) in human immunode-
ficiency virus/hepatitis C virus (HIV/HCV) coinfected patients. Using a proteomic approach, we identified high
levels of IFNa receptor 2a (IFNaR2a) in the serum of null responders to pegIFNa/RBV. IFNaR2a inhibited
antiviral activity of all formulations of IFNa in JFH/Huh7.5 cells. Furthermore, serum from null responders, but
not from those who achieved sustained virologic response, suppressed IFN-signaling and ISG expression in
IFNa-stimulated PBMCs of healthy donors in an IFNaR2a specific fashion. An IFNaR2a transgenic mice model
(C57BL/6) was generated that had significantly higher levels of IFNaR2a in the serum than the controls
(P = 0.001). Total ISG expression in the lymph nodes was significantly higher compared to wild-type mice
(P value = 0.0016). In addition, IFITM1 and SP110 had significantly increased expression in the liver, IFITM1 and
ISG15 in the lymph node, and ISG15 and PLSCR1 in the spleen (P value < 0.05). The underlying mechanism of
resistance to hepatitis C treatment may involve transsignaling of the JAK/STAT pathway by the sIFNaR2a-
IFNa/b complex and result in the enhanced ISG signature observed in null responders. In this regard, the
transgenic mice model simulated nonresponders to IFNa therapy and provides valuable insights into the role of
sIFNaR2a-IFNa interactions in vivo.
Introduction
Hepatitis C virus (HCV) is a single-stranded, envel-oped, positive sense RNA virus that causes both acute
and chronic hepatitis. Chronic HCV infection occurs in 60%–
80% of patients with acute infection and can lead to many
complications of the liver, including cirrhosis, hepatocellular
carcinoma, and hepatic failure (Fields and others 2007). Co-
infection of human immunodeficiency virus (HIV) with HCV
leads to higher HCV viral load, rapid progression of liver
fibrosis, liver-related mortality, and poor response to inter-
feron (IFN)-based treatment (Alter and others 1999).
The current standard of treatment for HCV infection in-
volves pegylated IFNa (pegIFNa) and ribavirin (RBV). This
regimen may achieve viral clearance or sustained virologic
response (SVR) in up to 30% of patients infected with HCV
genotype 1, but is significantly lower for those of African
descent or coinfected with HIV (Fried and others 2002;
Chung and others 2004; Muir and others 2004).
IFNs have remained the backbone of HCV treatment since
the 1990s (Poordad and Dieterich 2012). IFNs and their re-
ceptors (IFNaR1 and 2 heterodimer) are important in antiviral
and antiproliferative activities through the JAK-STAT signal-
ing paradigm (Schindler and others 2007). Modulated by the
IFNa receptor 1 (IFNaR1) and IFNa receptor 2 (IFNaR2), the
type I IFN regulates transcription of IFN stimulated genes
(ISGs) (Liu and others 2011). Several mechanisms have been
suggested as reasons for poor HCV clearance rates among
HIV/HCV coinfected subjects. Recently we showed an en-
hanced endogenous ISG signature that was associated with
lack of response to pegIFNa and RBV treatment in HIV/HCV
infected subjects (Lempicki and others 2006). However, only
limited data are available regarding the host and viral factors
that result in this enhanced ISG response in some but not all
HIV/HCV infected subjects. Furthermore, why these patients
do not respond to exogenous IFN is unclear.
In this study, we performed a proteomic approach to
identify soluble factors associated with the lack of response
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to IFN-based HCV treatment. We further tested the ability of
candidate proteins to interfere with IFN signaling in vitro and
in vivo using a transgenic mice model.
Materials and Methods
Study subjects
HIV/HCV coinfected study subjects were selected based
on previous treatment with pegIFNa2a (180 mg/week) or
pegIFNa2b (1.5 mg/kg/week) with weight based RBV (1.0–
1.2 g/day) for 48 weeks. Subjected belonged to 2 groups: (1)
null responder (NR) those who did not have more than 2 log
HCV RNA decline from baseline by 2 weeks of treatment
and (2) SVR: those who had less than detectable levels of
HCV RNA 24 weeks after stopping treatment. All patients
signed informed consent, which was approved by the Na-
tional Institute of Allergy and Infectious Diseases Institu-
tional Review Board.
Proteomic profiling of pooled serum
by antibody array
Pooled serum was used to detect differentially expressed
proteins using Cytokine 507 array (RayBiotech, Inc.) where
507 cytokine antibodies were printed on a microscope glass
slide. Pooled serum at day 0 and 3 was prepared by mixing
equal portions of 14 NR or 14 SVR. The samples were first
labeled with Cy3 and applied to the arrays in duplicate per
manufacturer’s protocol. The arrays were then scanned by
Agilent microarray scanner with 10 mm resolution and their
spot intensities were analyzed by Agilent Feature Extrac-
tion 9.0.
ELISA to quantify serum IFNaR2 levels
Blood was collected by venipuncture longitudinally
when subjects were undergoing treatment. Serum was
separated from whole blood, spun and stored at - 80C for
further use. Serum was thawed and levels of soluble
IFNaR2 in subjects were determined using the EIA kit
(Mybiosource, Inc.) per the manufacturers’ instructions. The
range of IFNaR2a detected by EIA was 25–1,600 pg/mL.
Serum samples were diluted 1/10 and 1/100 and tested in
duplicate.
In vitro assay for biological activity of IFNaR2
Ability of IFNaR2a (R&D Biosystems) to block anti-HCV
activity of various formulations of IFNa was determined
using JFH/Huh7.5 cells in continuous culture system as
previous described (Zhang and others 2009). Freshly isolated
PBMCs from healthy donors were incubated with human
sera from HIV/HCV coinfected (NR or SVR) and IFNa2b in
the presence or absence of IFNaR2a antibody (R&D Biosys-
tems). Total RNA was isolated and ISG expression was de-
termined using the Applied Biosystems Custom TaqMan
Expression Assay, a multiplex PCR platform.
Transgenic mice construction
Four founder clones were produced: (1) Mus musculus
IFNaR2a (Mmu.IFNaR2a) with aminoterminal Kozak
translation initiation sequence, (2) CAG2 promoter with the
chicken b-actin promoter with CMV enhancer, with the se-
quence based on the pCCALL2 series vectors, and containing
Gateway attL4 and attR1 sequences for multisite recombi-
nation, (3) albumin promoter with the sequence derived
from literature sources and cloned from a DNA already at
the NCI, Frederick Protein Expression Laboratory with
Gateway attL4 and attR1 sequences, and (4) Pol2 promoter
with the murine Pol2 promoter. These clones were com-
pletely sequenced to verify that they were correct and mat-
ched the expected database sequences. The clones were
spectinomycin-resistant, enabling growth in any Escherichia
coli strain using 50 mg/mL spectinomycin to maintain the
plasmids.
Expression clones were produced by using Multisite Gate-
way recombination to merge promoters with the IFNaR2a
gene into constructs utilized to generate transgenic mice.
Three expression clones were created, including the CAG-
Mmu.IFNaR2a, Alb-Mmu.IFNaR2a, and Pol2-Mmu.IFNaR2a.
DNA was prepared using the Sigma GenElute maxiprep kit
and verified by agarose gel electrophoresis.
The construct DNA from 3 expression clones were mi-
croinjected onto fertilized eggs of C57BL/6 mice to create the
first generation of IFNaR2a transgenic mice in the NIH ani-
mal facility in Frederick, MD and housed under the NIH
animal welfare rules and regulations. All 3 transgenic mice
strains were developed and confirmed to have over-
expression of sIFNaR2a. The presence of the transgene was
confirmed using the Sigma-Aldrich Extract-N-Amp Tissue
PCR kit and 2% agarose gel electrophoresis from mice tails.
The overexpression of sIFNaR2a was verified by Western
blot analysis using mice serum. Two microliters of serum
was added to 24 mL water, 10 mL 4 · LDS, and 4 mL b-Me
and heated for 10 min at 70C. Samples were run on - 12%
BT gels with 5% milk in TBS-T (0.05% T in TBS) as blocker.
The transgene was detected using 1mg/mL rat anti-IFNaR2
in 5% milk TBS-T and 1:10,000 anti-rat HRP in 5% milk
TBS-T.
The CAG-IFNaR2a transgenic mice with the chicken
b-actin promoter were backcrossed to produce the stable
second generation of transgenic mice (n = 9). C57BL/6 mice
were used as wild-type controls (n = 4).
ISG expression
RNA was extracted from lymph node, spleen, and liver of
6–12-week-old transgenic and control mice using the Qiagen
RNeasy Mini Kit and cDNA was generated using the
Applied Biosystems High-Capacity cDNA Archive Kit. Real-
time PCR was performed using the 96-well Applied Bio-
systems Custom TaqMan Expression Assay to analyze ISG
expression in each tissue type. The following ISGs were an-
alyzed: IFI27L1, IFITM1, IRF3, ISG15, ISG20, OAS1b,
PLSCR1, SP110, and STAT1. Each ISG expression was nor-
malized to that of GAPDH.
Statistical analysis
The F-test to compare variances and unpaired t-test were
used to determine statistical significance of high levels of
IFNaR2a and mean ISG expression in NR versus SVR. Paired
t-test was used to determine statistical significance of inhib-
itory effects of IFNaR2a on IFNa. A Student’s t-test was used
to determine statistical significance of ISG expression in
transgenic mice compared to control mice.
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Results
Null responders to PegIFN and RBV have increased
IFNaR2a in serum
To identify the soluble factors differentially expressed in
the serum of NR and SVR subjects, we performed protemic
analysis using an antibody array (Raybiotech). Twenty-five
proteins were selected based on criteria of P value < 0.05 and
fold change greater than 2 as shown in Fig. 1a. There were no
differences in proteomic levels between day 0 and 3 in both
NR and SVR subjects. Fifteen proteins were upregulated in
SVR compared to NR, and 10 proteins were upregulated
in NR compared to SVR. Among the 10 upregulated proteins
in NR, high levels of sIFNAR2a in the serum of NR were
validated using a confirmatory ELISA as shown in Fig. 1b by
the unpaired t-test (P value < 0.0001) and F-test to compare
variances (P value = 0.005). Due to the potential biological
significance of the molecule, IFNaR2a was selected for fur-
ther validation by EIA.
IFNaR2a inhibits antiviral activity of all formulations
of IFNa
We then tested whether the presence of high levels of IF-
NaR2a could inhibit the biological activity of IFNa. Figure 2
illustrates the inhibitory effect of IFNaR2a on different for-
mulations of IFNa in JFH/Huh7.5 cells. The addition of IF-
NaR2a reduced suppression of HCV replication by IFNa-2b
from 64.7% – 13.0% to 20.7% – 5.8% (P value = 0.0128). In
PegIFNa2b, suppression of HCV replication was reduced
FIG. 1. (a) Differential expression of serum proteins before
and 3 days after treatment with pegylated interferon a2 (pe-
gIFNa2) and ribavirin (RBV) among null responders (NR) and
sustained virologic responders (SVR). Serum proteins from 10
NR and 10 SVR human immunodeficiency virus/hepatitis C
virus (HIV/HCV) coinfected subjects were identified using a
Ray Biotech protein array as described in the materials and
methods. The differentially expressed proteins were selected
using a rigorous statistical analysis with a P value < 0.01 and
fold change > 2. The color red indicates high expression and
the green color indicates low expression of the respective
protein. Overall, there were no statistically significant differ-
ences in the expression of proteins between day 0 and 3 in
both groups. As shown in figure, 15 serum proteins were
expressed at lower levels on day 0 and 3 among NRs when
compared to the levels of expression in SVR. Similarly, 10
serum proteins were expressed at higher levels on day 0 and 3
among NR compared to that observed in SVR. (b) Elevated
levels of soluble IFNa/b receptor 2 in the serum of null re-
sponders, but not sustained responders who were treated
with pegIFNa2 and RBV. Levels of IFNa receptor 2a (IF-
NaR2a) in serum were quantified using an EIA as described in
the Materials and Methods section. As shown in Fig. 2, null
responders had significantly higher levels of soluble IFNaR2a
in their serum compared to SVR (P value < 0.0001).
FIG. 2. Soluble IFNa/b receptor 2 can inhibit the anti-HCV
effects of various IFNa formulations in vitro. Using an in vitro
HCV continuous culture system ( J6/JFH-1/Huh7.5), copy
numbers of J6/JFH-1 were quantitated by real-time PCR in
culture supernatants with or without addition of equimolar
IFNa formulations (IFNa2b, pegIFNa2a, pegIFNa2b, AlbIF-
Na2b) in the presence or absence of IFNa/b receptor 2 (5 mg/
mL) as described in the Materials and Methods section. As
shown in Fig. 3, all IFN formulations exhibited potent sup-
pression of HCV replication and addition of sIFNaR2 abro-
gated this effect significantly (all P values < 0.05).
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from 57.3% – 11.4% to 9.7% – 3.5% (P value = 0.0284). In Pe-
gIFNa2a, suppression of HCV replication was reduced from
59.7% – 10.3% to 7.0% – 2.6% (P value = 0.0095). In Alb-IFNa,
suppression of HCV replication was reduced from
75.3% – 4.6% to 6.0% – 2.0% (P value = 0.0018). Suppression of
HCV replication was dramatically reduced with the addition
of IFNaR2a in each of the formulations of IFNa.
Serum from NR suppress IFNa-mediated
ISG expression
We then determined whether serum from NR, which has
high levels of IFNaR2a, would have an effect on the biological
activity of IFNa. Freshly isolated PBMCs were stimulated
with recombinant IFNa with serum from NR and SVR in the
presence or absence of anti-IFNaR2a antibodies. As shown in
Fig. 3, serum from NR specifically inhibited ISG expression in
PBMCs (P value < 0.0001), which was abrogated by the addi-
tion of neutralizing anti-IFNaR2a antibodies (P value < 0.0001).
Sera from SVR had minimal effect on the expression of ISG
since they had lower levels of sIFNaR2a.
IFNaR2a expression in transgenic mice
Three lines of mice expressing IFNaR2a transgene were
generated as described in the methods. Two of them used
FIG. 3. Inhibition of IFNa signaling in peripheral mononu-
clear cells by serum from null responders is mediated by sol-
uble IFNaR2. Mean IFN-stimulated gene (ISG) expression
(n = 30) in PBMCs after treatment with 20 IU/mL of IFNa
in vitro for 60 min with or without serum from NR and SVR in
the presence or absence of anti-IFNaR2 antibody were mea-
sured by real-time PCR as described in the Materials and
Methods section. Expression of each ISG was normalized with
that of GAPDH and averaged for each experimental condition.
As shown in Fig. 4, incubation of serum from NR, but not from
SVR resulted in the suppression of IFNa mediated induction of
ISG (P value < 0.0001 and > 0.05, respectively). The inhibition of
IFN signaling by serum from NR was entirely reversed by
addition of antibodies to IFNaR2 (P value < 0.0001), which
suggest the mechanism of suppression is mostly, if not entirely,
mediated by interactions between IFNa and soluble IFNaR2
present at high levels in the serum of NRs. However, no such
effect was observed with SVR, as the levels of sIFNaR2 in the
serum of SVR are considerably lower (P value > 0.05).
FIG. 4. (a) Transgene expression in first generation IFNa-
R2a mice. The single bands in lanes 1–12 in the gel electro-
phoresis indicate the presence of the IFNaR2a transgene in
the CAG-IFNaR2a mice. The double bands in lanes 1–4 of
Alb-IFNaR2a mice and lanes 1–7 of Pol2-IFNaR2a mice in-
dicate presence of the IFNaR2a transgene and the control
gene. (b) Transgene protein expression in backcrossed IF-
NaR2a mice. Western blot analysis of serum from transgenic
mice was performed as described in the Materials and
Methods section. The arrow indicates the presence of IF-
NaR2a. 1844–1848 are the CAG-IFNaR2a transgenic mice
after back cross from the first generation mice. 5716 and 7871
are positive controls. 7242 is the Pol2-IFNaR2a first genera-
tion mouse. MW indicates molecular weight ladder and 7232
is the C57BL/6 control without the transgene.
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ubiquitous promoters, while the third used an albumin
promoter, restricting the expression of the transgene to the
liver. All mice were tested for presence of transgene as
shown in Fig. 4a and expression of transgene via western
blot in Fig. 4b.
Increased ISG expression in IFNaR2a
transgenic mice
To determine the effect of high expression of IFNaR2a on
IFN signaling, we performed multiplex PCR for ISG ex-
pression using various tissues from CAG-IFNaR2a trans-
genic mice as shown in Table 1. Total ISG expression in the
lymph node was significantly higher (P value = 0.0016)
compared to wild-type mice. In addition, IFITM1 (P value =
0.0420) and SP110 (P value = 0.0190) were identified to have
significantly increased expression in the liver, IFITM1 (P val-
ue = 0.0121) and ISG15 (P value = 0.0121) in the lymph node,
ISG15 (P value = 0.0091) and PLSCR1 (P value = 0.0182) in the
spleen.
Discussion
We describe a novel mechanism mediated by excess levels
of soluble IFNaR2 in the serum of patients who subsequently
failed to respond to IFNa treatment for hepatitis C. Fur-
thermore, using an in vitro system, we demonstrate that ex-
cess levels of IFNaR2a can inhibit IFN-mediated antiviral
activity against HCV. In this regard, serum from null re-
sponders inhibited IFNa signaling in an IFNaR2a specific
manner. Moreover, we developed an in vivo model of
transgenic IFNaR2a mice, which demonstrated enhanced
endogenous IFN signaling, suggesting transsignaling as a
mechanism of interference of soluble IFNaR2a with JAK/
STAT signaling.
In hepatitis C treatment with exogenous IFNa, several
theories exist to explain the different host responses (NR
versus SVR) to IFN treatment. Although PBMCs from NR
have increased baseline ISG expression in vivo as demon-
strated by DNA microarray and real-time PCR data (Lem-
picki and others 2006), PBMCs from NR and SVR respond to
IFNa similarly in vitro (data not shown). This suggests a role
for inhibitory mechanisms in vivo that determines such a
response. The higher basal levels of soluble IFNaR2a in NR
compared to SVR have been observed to possibly affect this
IFN-signaling pathway.
The mechanism by which sIFNAR2a would enhance the
endogenous ISG expression is not clearly understood. Recent
studies have demonstrated that soluble IFNaR2a is one
among 3 isoforms of the IFNaR2, which are generated by
alternative splicing in both human and mouse and produces
the transmembrane IFNaR2b, as well as the complete re-
ceptor IFNaR2c (Owczarek and others 1997; Hardy and
others 2001; de Weerd and others 2007). In the murine
model, IFNaR2a exhibited antagonistic and agonistic prop-
erties (Hardy and others 2001). Recombinant IFNaR2a acted
as a competitive inhibitor of type I IFN antiproliferative ac-
tivity in an in vitro assay. However, in the murine IFNaR2
knockout thymocytes, recombinant IFNaR2a produced an
antiproliferative response, suggesting transsignaling capa-
bility of the soluble receptor (Hardy and others 2001). The
specific mechanism of soluble IFNaR2a is not clear in its
interaction in vivo with endogenous and exogenous IFN,
especially when administered as therapy. After IFNa treat-
ment in patients with hepatitis C, expression of the IFNa/b
receptor in the liver was much stronger in SVR than NR,
suggesting host differences in response to IFN (Meng and
others 2005). Hence, the soluble form of IFNaR2 receptor
soluble may act as important regulators of immune response
as in the case on many other such cytokine receptors, in-
cluding IL-6 and IL-15 (Fernandez-Botran 1991). For exam-
ple, soluble receptors, IL-6R and IL-15R, have been shown as
agonists in enhancing stimulation of target immune cells.
Transsignaling is a process by which the soluble component
of a heterodimer can interact with the ligand and the mem-
brane bound counterpart resulting in partial activation of the
signaling pathway. In this regard, our data demonstrates
that sIFNaR2a can also act in such a manner and result in
activation of JAK/STAT pathway to enhance endogenous
IFN gene signature observed in HIV/HCV coinfected sub-
jects. Transsignaling has been previous described with both
IL-6 and IL-15 receptors. It has been shown that IL-6/sIL-6R
complex induces the dimerization of gp130 in cells to regu-
late intracellular signal transduction ( Jones and others 2005).
Similarly, the IL-15/IL-15Ra complex has been demonstrated
to have superior stabilization and increased bioactivity
Table 1. Increased Interferon Stimulated Gene Expression in sIFNa2a Transgenic Mice
Liver Lymph node Spleen
Transgenic
(avg. Ct – SD)
Wild type
(avg. Ct – SD) P value
Transgenic
(avg. Ct – SD)
Wild type
(avg. Ct – SD) P value
Transgenic
(avg. Ct – SD)
Wild type
(avg. Ct – SD) P value
IFI27L1 4.04 – 0.26 4.36 – 0.30 0.1119 9.66 – 2.32 6.32 – 4.42 0.1939 9.87 – 2.04 10.78 – 4.71 0.7273
IFITM1 8.82 – 0.71 9.69 – 0.60 0.0420a 5.20 – 0.16 5.67 – 0.14 0.0121a 5.32 – 0.19 5.12 – 0.21 0.1455
IRF3 3.33 – 0.45 3.62 – 0.43 0.2977 7.79 – 1.88 3.52 – 3.84 0.1333 6.32 – 1.82 6.97 – 3.12 0.7273
ISG15 6.80 – 0.46 6.80 – 0.84 0.8981 7.50 – 0.26 6.30 – 0.72 0.0121a 7.27 – 0.28 6.29 – 0.36 0.0091a
ISG20 8.14 – 0.51 8.07 – 0.30 0.5185 11.26 – 2.18 7.24 – 3.15 0.0848 7.55 – 1.46 7.70 – 1.90 0.8636
OAS1b 10.31 – 0.88 9.94 – 0.36 0.3636 14.35 – 2.10 10.44 – 3.78 0.1333 12.92 – 2.18 11.84 – 4.34 0.8889
PLSCR1 9.18 – 0.62 8.60 – 0.88 0.1469 8.21 – 0.13 8.11 – 1.37 0.4970 8.19 – 0.17 7.43 – 0.51 0.0182a
SP110 11.79 – 0.56 10.86 – 0.58 0.0190a 12.84 – 2.97 8.57 – 3.53 0.1939 12.73 – 2.09 12.39 – 4.75 0.8636
STAT1 7.91 – 0.78 8.32 – 0.60 0.1469 11.77 – 2.82 8.94 – 3.95 0.3758 11.89 – 3.10 11.17 – 6.51 0.7273
Total 7.81 – 2.67 7.81 – 2.41 0.9270 9.84 – 3.35 7.24 – 3.27 0.0016a 9.07 – 3.17 8.64 – 3.74 0.2770
aSignificantly different (P < 0.05) between the transgenic and wild-type samples.
ISG, interferon-stimulated gene; avg. Ct – SD, average cycle threshold numbers – standard deviation.
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manifesting in selective induction of natural killer and
CD8 + T cells (Rubinstein and others 2006; Bergamaschi and
others 2008, 2009). Our data demonstrating that IFNAR2a
transgenic mice have enhanced endogenous expression of
ISG, is consistent with this hypothesis and could contribute
to the IFN signature observed in NRs in vivo, most likely
by JAK/STAT phosphorylation, resulting in ISGF3–ISRE
interactions.
Elevated levels of soluble IFNaR2a (sIFNaR2a) in serum
and urine have been associated with hairy cell leukemia and
adenocarcinoma, resulting in high resistance to IFN therapy
(Novick and others 1992; Ambrus and others 2003). In hep-
atitis C, where treatment is mainly dependent on IFN ther-
apy, high levels of sIFNaR2a have been associated with poor
response rates to pegIFNa and RBV (Mizukoshi and others
1999). In this regard, soluble IFNaR2a may potentially act as
a blocking agent in the IFN-signaling pathway. As shown in
our experiments, we can block the pathway and inhibit the
antiviral activity of IFN. However, it was unclear how the
blocking of the pathway led to increased ISG expression.
Clinical data suggests that high baseline ISG and ISG15 are
negative predictors for treatment response in hepatitis C to
IFN treatment (Chen and others 2005; Sarasin-Filipowicz and
others 2008). Therefore, we generated the transgenic mice
with overexpression of IFNaR2a, which suggests that IF-
NaR2a leads to high endogenous IFN signaling.
In our proposed model, high levels of soluble IFNaR2 is
associated with a lack of response to exogenous IFN. We
propose that the excess amount of IFNaR2a is generated by
alternative splicing, probably as a result of a yet unidenti-
fied SNP in some but not all HCV-infected individuals. An
excess of IFNaR2a then combines with membrane bound
IFNaR1 and IFN and leads to phosphorylation of the JAK/
STAT pathway, resulting in an enhanced ISG expression
(transsignaling) in tissues, such as the liver. Finally, this
persistent activation most likely leads to further blunting of
JAK/STAT signaling, resulting in a lack of response to ex-
ogenous IFN.
Overall, these results suggest that high ISG expression
may explain most of the IFN signaling abnormalities de-
scribed in the hepatic and peripheral lymphatics in patients
with hepatitis C. Finally, further studies will extend these
observations in an IFN-free treatment paradigm to clarify the
role of high ISG expression in predicting treatment response.
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